Hawaii Biotech gets support for Dengue vaccine program
Additional support has been made available for the Dengue vaccine program developed by Hawaii Biotech, in which Australia's Avantogen holds a significant investment stake.
The Dengue clinical trial will be conducted as part of a broader study at the clinical trials center of the US Walter Reed Army Institute of Research (WRAIR). This institution has a well recognized competency in emerging infectious disease and considerable experience with Dengue fever, the firm notes.
Avantogen believes that a partnership with a reputable organization such as WRAIR gives further validation of the Hawaii Biotech vaccine technology platform and the actual Dengue vaccine candidate that has been developed. Furthermore, Avantogen (and Hawaii Biotech) have also gained a potential partner to accelerate the program. Next steps could be the dosage of first subjects with the proprietary, recombinant-DNA-based vaccine candidate being developed by Hawaii Biotech.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze